Institutional Implementation: Setting Up Tarlatamab Administration

Opinion
Video

Panelists discuss how the administration of tarlatamab requires thorough pretreatment screening, staff training, and close monitoring for immune-related adverse effects such as cytokine release syndrome, emphasizing the importance of patient education, rapid intervention, and specialized infrastructure for safe and effective treatment.

Summary for Physicians:

Protocol for Tarlatamab Administration:

  • Site Setup:
  • Pretreatment screening: Ensure patients meet eligibility, assess organ function, and check for contraindications.

  • Staff training: Ensure all staff are trained on administration protocols and handling potential toxicities.

  • Monitoring: Patients are monitored for immune-related adverse effects such as cytokine release syndrome (CRS), especially during the first dose.

Challenges:

  • Management of CRS:
  • Need for rapid intervention and close monitoring in case of severe reactions.
  • Patient Education:
  • Ensuring patients understand potential adverse effects and the importance of timely reporting.
  • Infrastructure:

Need for specialized facilities and equipment for infusion and monitoring, especially in the event of adverse reactions.

Recent Videos
2 experts in this video
2 experts in this video
2 experts are featured in this series.
2 experts are featured in this series.
4 experts in this video
2 experts in this video
Related Content